Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson
Merck
Colorcon
AstraZeneca

Last Updated: December 7, 2022

CLINICAL TRIALS PROFILE FOR BACITRACIN ZINC


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Bacitracin Zinc

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000635 ↗ Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine Completed Glaxo Wellcome N/A 1969-12-31 To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV infection in patients with AIDS is often associated with skin sores and frequent recurrences. Treatment with the drug acyclovir results in healing for most patients, but repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for the treatment of Herpes infections that occur in the eye. This study attempts to determine if trifluridine is useful for treating HSV sores that have not healed after treatment with acyclovir.
NCT00000635 ↗ Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV infection in patients with AIDS is often associated with skin sores and frequent recurrences. Treatment with the drug acyclovir results in healing for most patients, but repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for the treatment of Herpes infections that occur in the eye. This study attempts to determine if trifluridine is useful for treating HSV sores that have not healed after treatment with acyclovir.
NCT00132600 ↗ Clinical Evaluation of Bacitracin Completed Mekos Laboratories AS Phase 2 2005-04-01 The purpose of this study is to establish a concentration of a bacitracin-patch for diagnosing allergic contact dermatitis.
NCT00479193 ↗ Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds Withdrawn MetroHealth Medical Center Phase 1 2006-10-01 Patients will be screened at the initial visit to the burn center. If the patients are eligible according to the inclusion/exclusion criteria, consent for the study will be obtained. One of the investigators will identify two sites that appear to be the same depth on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. The depth of injury will be verified as partial thickness using laser doppler. Each site will be at least 4cm x 4cm in size. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. The dressing will then be applied. All dressings will be covered with cotton gauze and ace wraps. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale. It will be noted if the wound appears infected or if antibiotics are prescribed. The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
NCT00695578 ↗ Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed Wake Forest University Phase 4 2006-10-01 The purpose of this research study is to evaluate the use of Biafine Cream on wounds created by removal of actinic keratosis using cryotherapy in a clinical setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bacitracin Zinc

Condition Name

Condition Name for Bacitracin Zinc
Intervention Trials
Dental Caries 3
Burns 3
Allergic Contact Dermatitis 2
Burn, Partial Thickness 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bacitracin Zinc
Intervention Trials
Burns 5
Infections 4
Infection 4
Dental Caries 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bacitracin Zinc

Trials by Country

Trials by Country for Bacitracin Zinc
Location Trials
United States 29
Egypt 3
India 1
Brazil 1
Greece 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bacitracin Zinc
Location Trials
Kentucky 4
Massachusetts 3
New York 3
California 3
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bacitracin Zinc

Clinical Trial Phase

Clinical Trial Phase for Bacitracin Zinc
Clinical Trial Phase Trials
Phase 4 13
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bacitracin Zinc
Clinical Trial Phase Trials
Completed 14
Recruiting 6
Unknown status 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bacitracin Zinc

Sponsor Name

Sponsor Name for Bacitracin Zinc
Sponsor Trials
Healthpoint 3
Cairo University 3
University of Louisville 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bacitracin Zinc
Sponsor Trials
Other 38
Industry 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Colorcon
McKesson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.